Private equity firm Warburg Pincus is reportedly close to acquiring Pantherx Rare, a leading US specialty pharmacy focused on rare and orphan diseases, in a transaction valued at more than US$7 billion.

The deal reflects continued confidence in the rare disease market, where increasing numbers of precision medicines and advanced therapies are driving demand for specialised pharmacy services capable of managing complex treatment pathways and patient support programmes.

If completed, the acquisition would rank among the largest healthcare private equity transactions of the year, reinforcing investor interest in businesses positioned at the intersection of specialty pharmaceuticals, rare disease care and innovative therapeutic delivey